)
)
Seagen Investor Relations Material
Latest events
Q4 2022
Seagen
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Seagen Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Net product sales
Royalty revenues
Collaboration and license agreement revenues
Expenses by
Financials
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer. The company markets LONZA (vinorelbine tartrate) injection, which is used to treat various types of cancer. It also focuses on the development of Seaglass (poly-L-glutamic acid), a compound that is undergoing clinical study for the treatment of chemotherapy-induced nausea and vomiting (CINV). The company was formerly known as Ocean Pharmaceuticals, Inc. and changed its name to Seagen Inc. in August 1995. Seagen Inc. is based in Bothell, Washington.
Latest articles
)
House of Warhammer: The Inner Workings of Games Workshop
A look under the hood of Games Workshop, a high-margin business in an incredibly niche market, with sky-high stock returns.
15 Nov 2024
)
Crafting a Solid Equity Story: A Strategic Guide for Investor Relations Professionals
Craft a compelling equity story: Align narratives with data to attract ideal investors and build trust with Quartr Pro's powerful IR tools.
13 Nov 2024
)
Our List of 100 Eminent Serial Acquirers
Serial acquirers have deep experience in mastering value creation through reallocating resources across their portfolio of acquired companies.
12 Nov 2024
Ticker symbol
SGEN
Country
🇺🇸 United States